ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”ASH25 Highlight – Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Important new insights from a post-hoc analysis of the RENOVE randomized trial, evaluating safety during extended treatment (after ≥6 months of full-dose therapy) with apixaban or rivaroxaban by Prof Francis COUTURAUD
Key Findings (5-year outcomes):
• Clinically relevant bleeding (CRB): Similar between drugs at both full and reduced doses.
• Major bleeding: No significant differences across subgroups.
• Recurrent VTE: Low and comparable with both agents.
• Dose reduction: Consistently lowered CRB risk for both apixaban and rivaroxaban.
Takeaway:
Unlike early-treatment data where rivaroxaban shows higher bleeding risk, during extended therapy the safety profiles of apixaban and rivaroxaban appear equivalent. More trials are needed.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan
-
Jun 9, 2026, 02:28Andreas Calatzis: Chasing Biologically Inactive Heparin?
-
Jun 9, 2026, 02:16Javier Lagos Servellon: Reflections on Completing the University of Bern’s Stroke Medicine Program
-
Jun 8, 2026, 17:50From Bleeding to Swelling – A Shared Therapeutic Revolution in Rare Diseases – RPTH Journal
-
Jun 8, 2026, 17:36Sophia Delicou: Decoding Acute Pain Transfusion Reactions in Thalassemia
-
Jun 8, 2026, 16:21Ifeanyichukwu Ifechidere: Reflections on the UK NEQAS Coagulation and Haemostasis Conference
-
Jun 8, 2026, 16:00Despina Fotiou: Advancing Recognition Through Global Case Collaboration